The Regulatory Effect of Firm Size on Digital Transformation: An Empirical Study of Pharmaceutical Companies in China

企业规模对数字化转型的监管效应:以中国制药企业为例的实证研究

阅读:2

Abstract

Digital transformation (DT) has been a key way for pharmaceutical companies to enhance innovation and R&D capabilities, improve product quality, reduce costs, and create competitive advantages. The external environment factors and the internal conditions' factors are the main factors affecting the DT of pharmaceutical companies. This research aimed to probe the effects of the external environment factors, the internal conditions' factors, firm size, and control variables on the DT of pharmaceutical companies based on synergetics. Purposive sampling and snowball sampling were used in this research. In addition, this research collected 395 valid data from Chinese pharmaceutical companies through online questionnaires. This research used quantitative analysis, and SPSS and Amos software were applied to data processing analysis. The results of structural equation modelling (SEM) and regression analysis showed that the external environment factors and the internal conditions' factors had a significantly positive correlation with the DT of pharmaceutical companies, and the effects of the internal conditions on the DT of pharmaceutical companies were greater than that of the external environment. In addition, firm size positively moderated the relationship between the external environment, internal conditions, and the DT of pharmaceutical companies. The results of this research not only can provide theoretical reference for scholars but also put forward implementation suggestions of DT for Chinese pharmaceutical company managers.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。